DCE-MRI and MBI in Assessing Tumor Response to Chemotherapy in Patients With Triple Negative Breast Cancer
Recruiting
GE Healthcare
Early Phase 1
2016-11-07
This early phase I trial studies how well dynamic contrast enhanced molecular resonance
imaging (DCE-MRI) and technetium-Tc99m sestamibi molecular breast imaging (MBI) work in
assessing tumor response to chemotherapy in patients with triple negative breast cancer
(TNBC) who are undergoing chemotherapy. Investigational imaging scans such as MBI and DCE-MRI
may help researchers predict which patients may respond to treatment.
DCE-MRI and MBI in Assessing Tumor Response to Chemotherapy in Patients With Triple Negative Breast Cancer
Recruiting
National Cancer Institute (NCI)
Early Phase 1
2016-11-07
This early phase I trial studies how well dynamic contrast enhanced molecular resonance
imaging (DCE-MRI) and technetium-Tc99m sestamibi molecular breast imaging (MBI) work in
assessing tumor response to chemotherapy in patients with triple negative breast cancer
(TNBC) who are undergoing chemotherapy. Investigational imaging scans such as MBI and DCE-MRI
may help researchers predict which patients may respond to treatment.
DCE-MRI and MBI in Assessing Tumor Response to Chemotherapy in Patients With Triple Negative Breast Cancer
Recruiting
M.D. Anderson Cancer Center
Early Phase 1
2016-11-07
This early phase I trial studies how well dynamic contrast enhanced molecular resonance
imaging (DCE-MRI) and technetium-Tc99m sestamibi molecular breast imaging (MBI) work in
assessing tumor response to chemotherapy in patients with triple negative breast cancer
(TNBC) who are undergoing chemotherapy. Investigational imaging scans such as MBI and DCE-MRI
may help researchers predict which patients may respond to treatment.
This preview shows a limited data set Subscribe for full access, or try a Trial
MIRALUMA Market Analysis and Financial Projection
Last updated: May 5, 2026
Miraluma: Clinical-Stage Update, Market Analysis, and Projection
What is MIRALUMA and where does it sit in development?
No reliable, citable information is available in the prompt to identify:
The drug’s correct generic name, active moiety, sponsor, and indication
Its registrational status (e.g., phase, endpoints, trial IDs, enrollment, readouts)
Trial geography, sites, dosing, comparator, or safety/efficacy outcomes
Whether “MIRALUMA” is a brand, code name, or mis-spelling of another asset
Because MIRALUMA cannot be anchored to a specific, verifiable drug identity from the provided content, a complete clinical trials update and defensible market projection cannot be produced without introducing factual error.
Key Takeaways
MIRALUMA’s clinical development and market outlook cannot be quantified from the information provided.
No defensible trial update (phase, endpoints, timelines, outcomes) can be compiled without a verifiable drug identity.
No defensible market analysis or projection (pricing, TAM/SAM/SOM, launch timing, adoption curves) can be produced without a verifiable indication, mechanism, and clinical program.
FAQs
What does “MIRALUMA” refer to (generic, sponsor, indication)?
Not determinable from the provided prompt.
What phase is MIRALUMA in and what are its primary endpoints?
Not determinable from the provided prompt.
Are there published efficacy or safety readouts for MIRALUMA?
Not determinable from the provided prompt.
What is the projected launch timeline for MIRALUMA?
Not determinable from the provided prompt.
What is the addressable market and pricing basis for MIRALUMA?
Not determinable from the provided prompt.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
